U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07785154) titled 'A Registry-study of ELZONRIS in Participants With BPDCN' on Aug. 20.
Brief Summary: The main goal of this registry study is to investigate the effectiveness and safety of tagraxofusp in the treatment of adult participants with BPDCN in the real-world clinical practice setting.
Study Start Date: June 26, 2024
Study Type: OBSERVATIONAL
Condition:
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Intervention:
DRUG: Tagraxofusp
No study medication will be provided by the sponsor during this study.
Recruitment Status: RECRUITING
Sponsor: Stemline Therapeutics, Inc.
Published by HT Digital Content Services with permission fr...